Efficacy of Psychosocial Interventions in Men and Women With Sexual Dysfunctions-A Systematic Review of Controlled Clinical Trials: Part 2-The Efficacy of Psychosocial Interventions for Female Sexual Dysfunction Günzler and Berner Psychosocial Interventions in Female Sexual Dysfunction

Journal of Sexual Medicine

Volumn 9, Issue 12, 2012, Pages 3108-3125

  Günzler, Cindy ^a   Berner, Michael M ^a,b,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Psychosomatic Medicine and Psychotherapy   (Germany)

^c German Society for Psychiatry and Psychotherapy (DGPPN)   (Germany)

Author keywords

Controlled trial; Female sexual dysfunction; Psychosocial intervention; Psychotherapy; Randomized; Systematic review

Indexed keywords

ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONFLICT MANAGEMENT; CONTROLLED CLINICAL TRIAL (TOPIC); DYSPAREUNIA; ERECTILE DYSFUNCTION; FEMALE; FEMALE SEXUAL DYSFUNCTION; FOLLOW UP; GROUP THERAPY; HUMAN; MASTURBATION; PREMATURE EJACULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX THERAPY; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY; SOCIAL ADAPTATION; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION; VAGINAL DISCOMFORT; VAGINISM; VULVAR VESTIBULITIS;

EID: 84870575616     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02965.x     Document Type: Article

References (68)

1. Heiman JR. Sexual dysfunction: Overview of prevalence, etiological factors, and treatments. J Sex Res 2002;39:73-8.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008;5:777-87.
4. Christensen BS, Gronbaek M, Osler M, Pedersen BV, Graugaard C, Frisch M. Associations between physical and mental health problems and sexual dysfunctions in sexually active Danes. J Sex Med 2011;8:1890-902.
5. Shindel AW, Eisenberg ML, Breyer BN, Sharlip ID, Smith JF. Sexual function and depressive symptoms among female North American medical students. J Sex Med 2011;8:391-9.
6. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006;13:46-56.
7. Hartmann U, Heiser K, Ruffer-Hesse C, Kloth G. Female sexual desire disorders: Subtypes, classification, personality factors and new directions for treatment. World J Urol 2002;20:79-88.
8. Kelly MP, Strassberg DS, Turner CM. Behavioral assessment of couples' communication in female orgasmic disorder. J Sex Marital Ther 2006;32:81-95.
9. Kelly MP, Strassberg DS, Turner CM. Communication and associated relationship issues in female anorgasmia. J Sex Marital Ther 2004;30:263-76.
10. Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339-42.
11. Landry T, Bergeron S, Dupuis MJ, Desrochers G. The treatment of provoked vestibulodynia: A critical review. Clin J Pain 2008;24:155-71.
12. Walsh KE, Berman JR. Sexual dysfunction in the older woman: An overview of the current understanding and management. Drugs Aging 2004;21:655-75.
13. Bergeron S, Binik YM, Khalife S, Pagidas K, Glazer HI, Meana M, Amsel R. A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain 2001;91:297-306.
14. Foster DC. Vulvar disease. Obstet Gynecol 2002;100:145-63.
15. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, Poleshuck EL, Stodgell CJ, Dworkin RH. Oral desipramine and topical lidocaine for vulvodynia: A randomized controlled trial. Obstet Gynecol 2010;116:583-93.
16. Caruso S, Intelisano G, Farina M, Di Mari L, Agnello C. The function of sildenafil on female sexual pathways: A double-blind, cross-over, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2003;110:201-6.
17. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367-77.
18. Kaplan SA, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE, Martins AC. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-6.
19. Berman JR, Berman LA, Toler SM, Gill J, Haughie S, Study S. Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003;170:2333-8.
20. Alexander MS, Rosen RC, Steinberg S, Symonds T, Haughie S, Hultling C. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011;48:273-9.
21. Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: Faulty protocols or paradigms? J Sex Med 2010;7:858-72.
22. Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey SR, Foster VJ, Bolden-Watson C, Metz A. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303-16.
23. Ginzburg R, Wong Y, Fader JS. Effect of bupropion on sexual dysfunction. Annals of. Pharmacotherapy 2005;39:2096-9.
24. Jordan R, Hallam TJ, Molinoff P, Spana C. Developing treatments for female sexual dysfunction. Clin Pharmacol Ther 2011;89:137-41.
25. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: A double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008;5:887-97.
26. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006;3:628-38.
27. Simon JA. Opportunities for intervention in HSDD. J Fam Pract 2009;58:S26-30.
28. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2007;4:227-34.
29. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 Study. Menopause 2006;13:770-9.
30. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
31. Basson R. Testosterone therapy for reduced libido in women. Ther Adv Endocrinol Metab 2010;1:155-64.
32. ® Efficacy Trials. 2011. Available at: http://www.biosantepharma.com/News-Releases.php?ID=121411 (accessed September 14, 2012).
33. Masters WH, Johnson VE. Human sexual inadequacy. Toronto, New York: Bantam Books; 1970.
34. Heiman JR. Psychologic treatments for female sexual dysfunction: Are they effective and do we need them? Arch Sex Behav 2002;31:445-50.
35. Perel E. Mating in captivity: Reconciling the erotic and the domestic. New York: HarperCollins; 2006.
36. Clement U. Sex in long-term relationships: A systemic approach to sexual desire problems. Arch Sex Behav 2002;31:241-6.
37. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. Annu Rev Sex Res 1997;8:148-94.
38. McGuire H, Hawton K. Interventions for vaginismus. Cochrane Database Syst Rev 2003;(1):CD001760. DOI: 10.1002/14651858.CD001760.
39. Leiblum SR, Wiegel M. Psychotherapeutic interventions for treating female sexual dysfunction. World J Urol 2002;2:127-36.
40. McGloin L, Carey JC. Orgasmic dysfunction. Obstet Gynecol Clin North Am 2006;33:579-87.
41. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
42. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
43. Berner M, Günzler C. Efficacy of psychosocial interventions in men and women with sexual dysfunctions-A systematic review of Controlled Clinical Trials Part 1-The efficacy of psychosocial interventions for male sexual dysfunction. J Sex Med 2012 [Epub ahead of print] doi: 10.1111/j.1743-6109.2012.02970.x.
44. LoPiccolo J, Heiman JR, Hogan DR, Roberts CW. Effectiveness of Single therapists versus cotherapy teams in sex therapy. J Consult Clin Psychol 1985;53:287-94.
45. van Lankveld JJ, Everaerd W, Grotjohann Y. Cognitive-behavioral bibliotherapy for sexual dysfunctions in heterosexual couples: A randomized waiting-list controlled clinical trial in the Netherlands. J Sex Res 2001;38:51-67.
46. ter Kuile MM, van Lankveld JJ, de Groot EH, Melles R, Neffs J, Zandbergen M. Cognitive-behavioral therapy for women with lifelong vaginismus: Process and prognostic factors. Behav Res Ther 2007;45:359-73.
47. van Lankveld JJ, Melles R, Nefs J, Zandbergen M, ter Kuile MM, de Groot EH. Cognitive-behavioral therapy for women with lifelong vaginismus: A randomized waiting-list controlled trial of efficacy. J Consult Clin Psychol 2006;74:168-78.
48. Stravynski A, Gaudette G, Lesage A, Arbel N, Bounader J, Lachance L, Clerc D, Fabian J, Lamontagne Y, Langlois R, Lipp O, Sidoun P. The treatment of sexually dysfunctional women without partners: A controlled study of three behavioural group approaches. Clin Psychol Psychother 2007;14:211-20.
49. Kilmann PR, Mills K, Caid C, Davidson E, Bella B, Milan R, Drose G, Boland J, Follingstad D, Montgomery B, Wanlass R. Treatment of secondary orgasmic dysfunction: An outcome study. Arch Sex Behav 1986;15:211-29.
50. Trudel G, Marchand A, Ravart M, Aubin S, Turgeon L, Fortier P. The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. Sex Relat Ther 2001;16:145-64.
51. Hurlbert DF. A comparative study using orgasm consistency training in the treatment of women reporting hypoactive sexual desire. J Sex Marital Ther 1993;19:41-55.
52. Hurlbert DF, White C, Powel DR. Orgasm consistency training in the treatment of the women reporting hypoactive sexual desire: An outcome comparison of women-only groups and couples-only groups. J Behav Ther Exp Psychiatry 1993;24:3-13.
53. MacPhee D, Johnson SM, Van der Veer MM. Low sexual desire in women: The effects of marital therapy. J Sex Marital Ther 1995;21:159-82.
54. Trudel G, Saint-Laurent S, Proulx S. Traitement Béhavioral des Dysfonctionnements Sexuels par Bibliothérapie: Les Résultats de Deux Études. Revue de modification du comportement 1985;15:76-81.
55. Spence SH. Group versus individual treatment of primary and secondary female orgasmic dysfunction. Behav Res Ther 1985;23:539-48.
56. Bergeron S, Khalife S, Glazer H, Binik Y. Surgical and behavioral treatments for vestibulodynia: Two-and-one-half-year follow-up and predictors of outcome. Obstet Gynecol 2008;111:159-66.
57. Weijmar Schultz WCM, Gianotten WL, van der Meijden WI, van de Wiel HBM, Blindeman L, Chadgha S, Drogendijk AC. Behavioral approach with or without surgical intervention to the vulvar vestibulitis syndrome: A prospective randomized and non-randomized study. J Psychosom Obstet Gynaecol 1996;17:143-8.
58. Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical lidocaine gel: A randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand 2006;85:1360-7.
59. Masheb RM, Kerns RD, Lozano C, Minkin MJ, Richman S. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. Pain 2009;141:31-40.
60. Schnyder U, Schnyder-Lüthi C, Ballinari P, Blaser A. Therapy for vaginismus: In vivo versus in vitro desensitization. Can J Psychiatry 1998;43:941-4.
61. Zimmer D. Does marital therapy enhance the effectiveness of treatment for sexual dysfunction? J Sex Marital Ther 1987;13:193-209.
62. Zimmer D. Motivational issues in premature termination of treatment for sexual dysfunction. Sex Marital Ther 1987;2:153-61.
63. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a primary care setting: A survey finding. J Sex Med 2010;7:3080-7.
64. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: Prevalence and associated risk factors. Int J Impot Res 2006;18:382-95.
65. Metz ME, Epstein N. Assessing the role of relationship conflict in sexual dysfunction. J Sex Marital Ther 2002;28:139-64.
66. Grawe K. [(How) can psychotherapy be more effective by empirical validation?]. [German]. Psychother J 2005;1:4-11.
67. Jones LM, McCabe MP. The effectiveness of an Internet-based psychological treatment program for female sexual dysfunction. J Sex Med 2011;8:2781-92.
68. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009;(1):MR000006.